Approaches to the treatment of diseases of the lower respiratory tract: choice of antibacterial preparati on taking into account international recommendations

S.O. Kramarov, L.V. Zakordonets


Acute respiratory infection is a leading cause of morbidity and mortality among children in the world, especially in young children. Solving the issue of the need to prescribe antibiotic therapy remains a difficult problem. Approaches to the treatment vary somewhat in different countries, depending on their economic status, the use of mass vaccination against pneumococcus and Haemophilus influenza b, and the local level of resistance to the major pathogens of respiratory infections. The article presents data of the international recommendations on antibacterial therapy of infections of the lower respiratory tract.


infections of the lower respiratory tract; children; pneumonia; bronchitis; antibiotics; azithromycin


GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018 Nov;18(11):1191-1210. doi: 10.1016/S1473-3099(18)30310-4.

World Health Organization. Pneumonia. Available from: Accessed: November 7, 2016.

Rodríguez L, Cervantes E, Ortiz R. Malnutrition and gastrointestinal and respiratory infections in children: a public health problem. Int J Environ Res Public Health. 2011 Apr;8(4):1174-205. doi: 10.3390/ijerph8041174.

Black RE , Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010 Jun 5;375(9730):1969-87. doi: 10.1016/S0140-6736(10)60549-1.

Lynnyk MI, Nedospasova OP, Tarasenko OR, Kapustjak VI, Bushura IV, Nikiforova LG. Porivnjal'ni dani pro rozpovsjudzhenist' hvorob organiv dyhannja i medychnu dopomogu hvorym na hvoroby pul'monologichnogo ta alergologichnogo profilju v Ukrai'ni za 2010-2016 rr [Comparative data on the prevalence of respiratory diseases and medical care for patients with pulmonary and allergic diseases in Ukraine in 2010-2016]. Kyiv: Lira-K; 2017. 48 p. (in Ukrainian).

Zar HJ, Cotton MF. Nosocomial pneumonia in pediatric patients: practical problems and rational solutions. Paediatr Drugs. 2002;4(2):73-83. doi: 10.2165/00128072-200204020-00001.

Ostapchuk M, Roberts DM, Haddy R. Community-acquired pneumonia in infants and children. Am Fam Physician. 2004 Sep 1;70(5):899-908.

Tackett KL, Atkins A. Evidence-Based Acute Bronchitis Therapy. J Pharm Pract. 2012 Dec;25(6):586-90. doi: 10.1177/0897190012460826.

Centers for Disease Control and Prevention (CDC). Mycoplasma pneumoniae outbreak at a university - Georgia, 2012. MMWR Morb Mortal Wkly Rep. 2013 Aug 2;62(30):603-6.

Ning G, Wang X, Wu D, et al. The etiology of community-acquired pneumonia among children under 5 years of age in mainland China, 2001-2015: A systematic review. Hum Vaccin Immunother. 2017 Nov 2;13(11):2742-2750. doi: 10.1080/21645515.2017.1371381.

Gonzales R, Sande M. Uncomplicated acute bronchitis. Ann Intern Med. 2000 Dec 19;133(12):981-91.

American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006 Oct;118(4):1774-93. doi: 10.1542/peds.2006-2223.

Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502. doi: 10.1542/peds.2014-2742.

Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008 May;86(5):408-16.

Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011 Oct;66 Suppl 2:ii1-23. doi: 10.1136/thoraxjnl-2011-200598.

Wen Z, Wei J, Xue H, et al. Epidemiology, microbiology, and treatment patterns of pediatric patients hospitalized with pneumonia at two hospitals in China: a patient chart review study. Ther Clin Risk Manag. 2018 Mar 13;14:501-510. doi: 10.2147/TCRM.S143266.

Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and x-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004977. doi: 10.1002/14651858.CD004977.pub2.

Public Health England. Pneumococcal Disease. Available from: Accessed: July 14, 2014.

Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004 Apr;113(4):701-7.

Rogozinski LE, Alverson BK, Biondi EA. Diagnosis and treatment of Mycoplasma pneumoniae in children. Minerva Pediatr. 2017 Apr;69(2):156-160. doi: 10.23736/S0026-4946.16.04866-0.

Meyer Sauteur PM, Roodbol J, Hackenberg A, et al. Severe childhood Guillain-Barré syndrome associated with Mycoplasma pneumoniae infection: a case series. J Peripher Nerv Syst. 2015 Jun;20(2):72-8. doi: 10.1111/jns.12121.

Jin X, Zou Y, Zhai J, Liu J, Huang B. Refractory Mycoplasma pneumoniae pneumonia with concomitant acute cerebral infarction in a child case report and literature review. Medicine (Baltimore). 2018 Mar;97(13):e0103. doi: 10.1097/MD.0000000000010103.

Zhan P, Suo LJ, Qian Q, et al. Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis. Eur J Cancer. 2011 Mar;47(5):742-7. doi: 10.1016/j.ejca.2010.11.003.

Hahn DL, Schure A, Patel K, Childs T, Drizik E, Webley W. Chlamydia pneumoniae-specific IgE is prevalent in asthma and is associated with disease severity. PLoS One. 2012;7(4):e35945. doi: 10.1371/journal.pone.0035945.

Torumkuney D, Pertseva T, Bratus E, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014–16 in Ukraine and the Slovak Republic. J Antimicrob Chemother. 2018 Apr 1;73(suppl_5):v28-v35. doi: 10.1093/jac/dky069.

Centre for Clinical Practice at NICE (UK). Respiratory Tract Infections - Antibiotic Prescribing: Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in Adults and Children in Primary Care. NICE Clinical Guideline 69. London: National Institute for Health and Clinical Excellence (UK); 2008 Jul.

National Institute for Health and Care Excellence (UK). Pneumonia in adults: diagnosis and management. NICE Clinical Guideline 19. Available from: Accessed: December 2014.

Lim WS, Baudouin SV, George RC,et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009 Oct;64 Suppl 3:iii1-55. doi: 10.1136/thx.2009.121434.

Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011 Oct;53(7):e25-76. doi: 10.1093/cid/cir531.

Messinger A, Kupfer O, Hurst A, Parker S. Management of Pediatric Community-acquired Bacterial Pneumonia. Pediatr Rev. 2017 Sep;38(9):394-409. doi: 10.1542/pir.2016-0183.

Agence Française de Sécurité Sanitaire des Produits de Santé. Systemic antibiotic treatment in upper and lower respiratory tract infections: official French guidelines. Clin Microbiol Infect. 2003 Dec;9(12):1162-78.

Strachunsky LS, Zharkova LP, Kvirkveliya MA, Tsibina LV, Avdeeva TG, Shavrikova EP. Treatment of pediatric community-acquired pneumonia by short course of Azithromycin (results of randomized trial). Pediatria. 1997;76(5):91-96. (in Russian).

Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001954. doi: 10.1002/14651858.CD001954.pub3.

Budanov SV. Azithromycin (Sumamed®) - main properties and treatment of community-acquired pneumonia. Antibiotics and chemotherapy. 2010;45(10):28-37.

Community Acquired Pneumonia Guidelines. Available from: Accessed: January 08, 2018.

Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis E, Perletti G4, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014 Aug;143(2):225-45. doi: 10.1016/j.pharmthera.2014.03.003.

Zupanets I, Bezuglaia N, Libina V, et al. Assessment of interchangeability of Azimed - bioequivalence is proved! Liky Ukrai'ny. 2013;(1):57-60. (in Russian).

Copyright (c) 2018 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта